Kurt Schmidt has been appointed CEO of Skyline Diagnostics. Schmidt joins Skyline from Agendia, where he had served as chief financial officer since 2009. Before Agendia, Schmidt was operations director at B2eMarkets and he was director of finance and operations at LA Gear Europe. In connection with Schmidt's appointment, Skyline's former CEO Henk Viëtor has been appointed to the supervisory board of the Rotterdam, Netherlands-based company.
In a statement, Skyline noted that Agendia is "not dissimilar" to itself, as it has also commercialized microarray-based tests for cancer. The firm also said that it is "entering a new phase" with Schmidt's appointment. Skyline achieved a CE-IVD mark for its AMLprofiler test in 2011 and is conducting clinical trials for an eventual US Food and Drug Administration submission (BAN 3/15/2011).